[DHQ of Taxifolin] DHQ Co., Ltd. and the National Cerebral and Cardiovascular Center begin considering implementation of “joint research on the prevention/treatment of dementia using Taxifolin”
*View in browser* *DHQ Co., Ltd.*
Press release: April 1, 2024
**
DHQ Co., Ltd. and the National Cerebral and Cardiovascular Center begin considering implementation of “joint research on taxifolin dementia prevention/treatment”
*~A new approach to dementia prevention/treatment by combining the antiplatelet drug cilostazol and the food ingredient taxifolin~* DHQ Co., Ltd. (Headquarters: Saitama City, Saitama
Prefecture/President: Teizo Yoshioka) has recently received an award from the National Cerebral and Cardiovascular Center (hereinafter referred to as Kokucirca), a national research and development corporation, for an invention related to a patent application related to the use of taxifolin “Dementia We have concluded an option agreement that gives us preferential negotiation rights (the right to negotiate for the introduction of drugs preferentially over others) regarding the exclusive implementation of “drugs for the prevention and/or treatment of.” In line with this, we have decided to consider starting a joint research project with Kokushin regarding the prevention and treatment of dementia using taxifolin.
This patent application relates to a new dementia prevention/treatment application by combining the antiplatelet drug cilostazol, which has already been approved in Japan, and the food ingredient taxifolin, which is attracting attention for its anti-inflammatory effects. .
[Development of dementia prevention/treatment drugs focusing on the brain’s waste excretion function]
Cerebral amyloid angiopathy (CAA) is a disease that can cause cerebral hemorrhage and cerebral infarction, and is closely related to Alzheimer’s disease, which accounts for 60-70% of all dementia cases. However, no effective treatment has been established at this time. Recently, CAA has been attracting a lot of attention due to its association with amyloid-associated imaging abnormalities (ARIA), a side effect that occurs when administering antibody drugs for Alzheimer’s disease. One of the causes of CAA is impaired excretion of a substance called amyloid-β (Aβ). Aβ should originally be excreted from the brain, but if it is not excreted properly, it will be deposited on the walls of small and medium-sized arteries in the brain.
It has been confirmed that this Aβ deposition overlaps with the IPAD (transarterial intramural drainage) pathway*1, a pathway that excretes nerve cell-derived waste products out of the brain. Combination therapy of cilostazol and taxifolin is thought to improve the impaired Aβ excretion by activating the function of the IPAD pathway, potentially leading to the treatment of CAA. This combination therapy has high expectations as a new dementia prevention/treatment drug because it is highly safe and has a low economic burden on patients.
(Cilostazol)
Cilostazol is an antiplatelet drug used to prevent recurrence after cerebral infarction such as lacunar infarction.
National circulation research has confirmed that cilostazol reduces Aβ deposition in the brain of Tg-SwDI mice*2 and improves cognitive dysfunction.
(taxifolin)
Taxifolin is a type of catechol-type flavonoid found in plants such as Dahlia larch. It is known to have excellent antioxidant and
anti-glycation effects.
National Circulation has revealed that the combination of cilostazol’s reduction in Aβ deposition and taxifolin’s inhibition of Aβ
oligomerization produces a synergistic effect in promoting Aβ excretion in the brain.
This patent focuses on impaired amyloid-β excretion, which is one of the causes of Alzheimer’s disease progression. It is also an innovative technology that combines the existing drug cilostazol and the food ingredient taxifolin. DHQ Co., Ltd. is doing its best to put this patent into practical use.
Furthermore, DHQ Co., Ltd. will continue to explore the potential applications of taxifolin in the medical field, thereby contributing to solving social problems related to people’s health and welfare.
*1 This is a pathway for excreting waste products in the brain, especially amyloid β, and its dysfunction is associated with Alzheimer’s disease and brain amyloid.
It is associated with the development of vasculopathy (CAA).
*2 Transgenic mice used for research on Alzheimer’s disease and cerebral amyloid angiopathy.
[About the National Cerebral and Cardiovascular Center]
・Location: 6-1 Kishibe Shinmachi, Suita City, Osaka Prefecture ・Chairman: Kinya Otsu
・Summary: It consists of three departments: “Hospital”, “Research Institute”, and “Open Innovation Center”, and its major feature is the integrated operation of the three departments. We are promoting comprehensive countermeasures against cardiovascular diseases, including heart disease, vascular disease, and stroke in adults and children.
・Hospital size: 550 inpatient beds
・Official website: https://www.ncvc.go.jp/
[Overview of DHQ Co., Ltd.]
DHQ Co., Ltd. was founded in 2008. Concluded an exclusive import agreement for Lavitol (R) with Amethis, the world’s top manufacturer of taxifolin raw materials. We are the first taxifolin supplier in Japan and continue to grow day by day as a leading company in the taxifolin business.
・Head office location: 308-5 Sachigawa, Nishi-ku, Saitama City, Saitama Prefecture
・Representative name: Teizo Yoshioka
・Business details: Import and sales of taxifolin, product development using taxifolin
・Company website: https://www.dhq.co.jp/
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000001.000116767.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=116767&release_id=1